Agilent/$A
1D1W1MYTD1Y5YMAX
Capital at risk
About Agilent
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
- Ticker
- $A
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 18,200
- Headquarters
- Santa Clara, United States
- Website
- www.agilent.com
Agilent Metrics
BasicAdvanced
$41B
28.94
$5.07
1.24
$1.01
0.69%
Price and volume
Market cap
$41B
Beta
1.24
52-week high
$163.75
52-week low
$108.35
Average daily volume
2.1M
Dividend rate
$1.01
Financial strength
Current ratio
2.05
Quick ratio
1.414
Long term debt to equity
0.522
Total debt to equity
0.563
Dividend payout ratio (TTM)
19.86%
Interest coverage (TTM)
17.07%
Profitability
EBITDA (TTM)
2,099
Gross margin (TTM)
53.83%
Net profit margin (TTM)
19.53%
Operating margin (TTM)
24.54%
Effective tax rate (TTM)
13.15%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
8.72%
Return on equity (TTM)
20.97%
Valuation
Price to earnings (TTM)
28.944
Price to revenue (TTM)
5.625
Price to book
5.62
Price to tangible book (TTM)
29.01
Price to free cash flow (TTM)
32.732
Free cash flow yield (TTM)
3.06%
Free cash flow per share (TTM)
4.485
Dividend yield (TTM)
0.69%
Forward dividend yield
0.69%
Growth
Revenue change (TTM)
8.60%
Earnings per share change (TTM)
18.71%
3-year revenue growth (CAGR)
1.77%
10-year revenue growth (CAGR)
5.98%
3-year earnings per share growth (CAGR)
9.87%
10-year earnings per share growth (CAGR)
13.40%
3-year dividend per share growth (CAGR)
4.61%
10-year dividend per share growth (CAGR)
8.57%
What the Analysts think about Agilent
Analyst ratings (Buy, Hold, Sell) for Agilent stock.
Analyst projections of the future price of Agilent stock.
Bulls say / Bears say
Agilent delivered strong Q3 fiscal 2026 results, with revenue up 8.1% reported and 7.3% core, while non-GAAP EPS rose 18% year over year to $1.62. (Agilent)
Management raised fiscal 2026 revenue and EPS guidance, now targeting $7.49-$7.51 billion of revenue and $6.18-$6.21 of non-GAAP EPS, indicating continued operating momentum and confidence in improving end markets. (SEC)
The completed Biocare Medical acquisition expands Agilent’s pathology offering and is expected by management to improve first-year top-line growth, margins and the mix of recurring non-instrument revenue. (Agilent)
Q3 adjusted EPS and margin benefited from approximately $0.06 per share and 110 basis points, respectively, from tariff refunds; future guidance excludes additional refunds, creating a less favorable comparison for underlying earnings. (SEC)
The recovery remains uneven: Agilent reported declines in academia and government markets over the first nine months of fiscal 2026, while several businesses—including liquid chromatography-mass spectrometry in parts of Europe and the Americas—also declined. (SEC)
Tariff and geopolitical uncertainty remains a risk to costs, demand and cross-border operations; Agilent says additional tariffs or changing trade policies could pressure revenue and operating efficiency even after mitigation efforts. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Agilent Financial Performance
Revenues and expenses
Agilent Earnings Performance
Company profitability
Upcoming events
No upcoming events
Agilent News
AllArticlesVideos
Funds containing Agilent
AllUSDEURGBP
Fund name | Fund size | $A weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.39% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.39% |
iShares Healthcare Innovation£DRDR | £1B | 1.39% |
VanEck Morningstar Wide Moat€GMVM | €407M | 1.28% |
VanEck Morningstar Wide Moat£MOGB | £354M | 1.28% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.